Literature DB >> 15657730

[Facial pigmentation following therapy with terbinafine].

K Breuer1, B Völker, R Gutzmer, A Kapp, T Werfel.   

Abstract

A 65-year-old patient presented with grey-brownish maculae localized on the face. He had been treated with oral terbinafine due to onychomycosis, and the first spots manifested after 4 weeks of therapy. Other drugs were not taken by the patient, who was otherwise in a healthy condition. Histology showed melanin localized within macrophages in the upper and lower dermis. Cutaneous side effects are well described in patients treated with terbinafine and usually present as urticaria or eczema. Severe reactions may occur in rare cases. Hyperpigmentation has not yet been described as a consequence of oral terbinafine. Grey hyperpigmentation as it occurred in our patient has been described as a side effect of therapy with minocycline, amiodarone, tricyclic antidepressants, or heavy metals. This case report shows that drug-induced hyperpigmentation should also be considered if the patient takes drugs not known for this kind of side effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15657730     DOI: 10.1007/s00105-004-0888-z

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  10 in total

1.  Acute generalized exanthematous pustulosis induced by terbinafine.

Authors:  Maurizio Lombardo; Michele Cerati; Alberto Pazzaglia
Journal:  J Am Acad Dermatol       Date:  2003-07       Impact factor: 11.527

Review 2.  Terbinafine: a review of its use in onychomycosis in adults.

Authors:  Malcolm J M Darkes; Lesley J Scott; Karen L Goa
Journal:  Am J Clin Dermatol       Date:  2003       Impact factor: 7.403

3.  [Reproducible drug exanthema to terbinafine with characteristic distribution of baboon syndrome].

Authors:  J M Weiss; M Mockenhaupt; E Schöpf; J C Simon
Journal:  Hautarzt       Date:  2001-12       Impact factor: 0.751

Review 4.  Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis.

Authors:  A K Gupta; R G Sibbald; S R Knowles; C W Lynde; N H Shear
Journal:  J Am Acad Dermatol       Date:  1997-05       Impact factor: 11.527

5.  Stevens-Johnson syndrome after terbinafine therapy.

Authors:  B Rzany; M Mockenhaupt; W Gehring; E Schöpf
Journal:  J Am Acad Dermatol       Date:  1994-03       Impact factor: 11.527

6.  Terbinafine and erythema multiforme.

Authors:  J M McGregor; M H Rustin
Journal:  Br J Dermatol       Date:  1994-10       Impact factor: 9.302

7.  Terbinafine-induced subacute cutaneous lupus erythematosus.

Authors:  G Bonsmann; M Schiller; T A Luger; S Ständer
Journal:  J Am Acad Dermatol       Date:  2001-06       Impact factor: 11.527

Review 8.  Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment.

Authors:  O Dereure
Journal:  Am J Clin Dermatol       Date:  2001       Impact factor: 7.403

Review 9.  Treatment of minocycline-induced cutaneous pigmentation with the Q-switched Alexandrite laser and a review of the literature.

Authors:  D Green; K J Friedman
Journal:  J Am Acad Dermatol       Date:  2001-02       Impact factor: 11.527

Review 10.  New histopathologic findings in drug eruptions.

Authors:  J E Fitzpatrick
Journal:  Dermatol Clin       Date:  1992-01       Impact factor: 3.478

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.